MISSISSAUGA, ON, April 14 /PRNewswire/ -- Anthony Giovinazzo, President & CEO of GB Therapeutics Ltd. (GBt), announced today that the company has changed its name from GB Therapeutics Ltd. to Cita NeuroPharmaceuticals Inc.
Project names have been changed from:
GT 1512 to CMP 1512
GT 3381 to CMP 3381
GT 1061 to CMP 1061
About Cita NeuroPharmaceuticals
Cita is a neuropharmaceutical company focussed on the development and commercialization of late stage small molecule drug candidates for neurological diseases and disorders. The Company leverages its clinical expertise, business acumen and strategic partnerships to identify, acquire, develop and market novel drugs. Cita's current portfolio consists of drugs for Parkinson's disease (CNP1512 entering Phase 3), neuropathic pain (CNP3381 entering Phase 2) and Alzheimer's disease (CNP1061 in preclinical development).
GB Therapeutics Ltd.
CONTACT: Anthony Giovinazzo, President & CEO, GB Therapeutics Ltd., 2480Dunwin Drive, Mississauga, Ontario, L5L 1J9, CANADA, Tel: (905) 607-4903ext 222, Fax: (905) 607-7351, Email: firstname.lastname@example.org